Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New corporate presentation

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Sep 26, 2022 9:37pm

118 Views

Post# 34988333

RE:RE:RE:RE:RE:RE:RE:RE:RE:New corporate presentation

I can't find anything explaining the sudden increase interest but it is not what JFM suggested as many of their previous PRs do mention business updates.
I am not even sure the trading was solely from the retail but they added 50 or more watchers on Stocktwits which are usually retail. I do agree the current undervaluation is due lack of belief in the prospect of THTX's commercial and R&D operations my issue with their marketing approach is targeting only institutional investors which is so unnecessary and frustrating that me it is and been a missed opportunity when the retail investors are still a big part of the investment community. I started a business last year in a competitive space, we spend heavily on the marketing from the beginning, google, social media platforms, pulling out construction permits

palinc2000 wrote:
How can you tell the trading today in the US was from retail?

I really thought that thru IR and other sources some investors have finally realized that the market cap did not even represent the value of existing legacy drug sales So the current SP does not take into account any increase in legacy drugs sales nor any potential positive development in the pipeline.

No downside and only upsides is a great investment thesis if you concur with that opinion

Why today?
I think it has been in the works for the past few weeks

scarlet1967 wrote:

2790bafc-6443-4aed-a90c-1cb2957c3330

2790bafc-6443-4aed-a90c-1cb2957c3330

https://www.theratech.com/static-files/8d86c08a-229e-4e9c-8ad2-ef353b8a4fbf

“Part 1 of the study is currently open to recruitment only in the USA. Once MTD, RD and safety are established, part 2 (expansion) will open in sites in the USA, UK, and Europe.”

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/clinical-trials

I can’t see anything new apart from SP and market cap.

I don’t look often at the website but there is a patient information page for Oncology , Hepatology which might not be new?

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/patient-need

https://www.theratech.com/medicines-pipeline/pipeline-and-science/hepatology/patient-need

Even mentioning opening sites in the USA, UK and Europe might not be new but they are there so it will be interesting when and how many more sites if any will start enrolling. The intraday volume increased significantly today and now there are more than there are more than 1000 followers on Stocktwits which must be record as long as I remember. Both are positive developments in my opinion so a bit more exposure, more liquidity, less volatility etc. Hopefully this is the start of an ongoing trend going forward.

I have said it many and too few times don’t underestimate the power of the retail investors!